<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926197</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-27492</org_study_id>
    <secondary_id>PANC0015</secondary_id>
    <secondary_id>NCI-2013-01658</secondary_id>
    <nct_id>NCT01926197</nct_id>
  </id_info>
  <brief_title>Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the safety and efficacy of a chemotherapy regimen&#xD;
      known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body&#xD;
      Radiotherapy (SBRT). We hope to learn if this new treatment combination helps to control the&#xD;
      disease and improve survival for patients with locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To determine progression free survival for mFFX +/- SBRT.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.&#xD;
&#xD;
        -  To determine the overall survival in pancreatic cancer patients treated with&#xD;
           chemotherapy +/- SBRT.&#xD;
&#xD;
        -  To determine local progression-free survival in pancreatic cancer patients after&#xD;
           chemotherapy +/- SBRT.&#xD;
&#xD;
        -  To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,&#xD;
           enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months of&#xD;
           treatment.&#xD;
&#xD;
        -  To evaluate the utility of FDG-PET for treatment planning and estimation of progression&#xD;
           free survival.&#xD;
&#xD;
        -  To identify new biomarkers in pancreatic cancer.&#xD;
&#xD;
        -  To evaluate the quality of life of patients before and after either chemotherapy or&#xD;
           chemotherapy and SBRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in progression-free survival between mFOLFIRINOX alone vs. mFOLFIRINOX and SBRT</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFIRINOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFFX+SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFIRINOX + SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the pancreas.&#xD;
&#xD;
          -  Induction mFolfirinox up to 4 cycles. Informed consent must be signed by the end of&#xD;
             the second cycle.&#xD;
&#xD;
          -  Stable or better disease on re-staging scans.&#xD;
&#xD;
          -  Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or&#xD;
             gastrointestinal oncology Tumor Board.&#xD;
&#xD;
          -  Typically, pancreatic tumors must be less than 8.0 cm in greatest axial dimension at&#xD;
             the time of treatment planning but final determination of eligibility will be based&#xD;
             upon satisfying the radiation normal tissue constraints as per protocol.&#xD;
&#xD;
          -  ECOG 0, 1, or 2&#xD;
&#xD;
          -  Patients must have acceptable organ and marrow function as defined below and within 30&#xD;
             days of eligibility confirmation:&#xD;
&#xD;
               -  leukocytes (WBC) &gt;=3,000/mL&#xD;
&#xD;
               -  absolute neutrophil count (ANC)&gt;=1,500mL&#xD;
&#xD;
               -  platelets &gt;=50,000/mL&#xD;
&#xD;
               -  total bilirubin &lt; or = 1.5 X institutional upper limit of normal&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt; or =2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  creatinine within normal institutional limits&#xD;
&#xD;
          -  Ability to understand and the willingness to sign an informed consent form.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Patients who have had prior radiotherapy to the upper abdomen/liver.&#xD;
&#xD;
          -  Patients who have received chemotherapy for pancreatic cancer, other than up to 4&#xD;
             cycles of mFolfirinox.&#xD;
&#xD;
          -  Children are excluded because pancreatic tumors rarely occur in this age group.&#xD;
             Furthermore, treatment requires a great deal of patient cooperation including the&#xD;
             ability to lie still for several hours in an isolated room.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection (or infections requiring systemic antibiotic treatment), symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder&#xD;
             cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy&#xD;
             without evidence of disease for &gt; 5 years will be allowed to enter the trial.&#xD;
&#xD;
          -  Pregnant and breastfeeding women are excluded; as well as women of child-bearing&#xD;
             potential who are unwilling or unable to use an acceptable method of birth control&#xD;
             (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the&#xD;
             duration of the study. Male subjects must also agree to use effective contraception&#xD;
             for the same period as above. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
          -  Women who are not post-menopausal (as defined in Appendix III) and have a positive&#xD;
             urine or serum pregnancy test or refuse to take a pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

